GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acrux Ltd (FRA:FJY) » Definitions » Debt-to-Asset

Acrux (FRA:FJY) Debt-to-Asset : 0.41 (As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Acrux Debt-to-Asset?

Acrux's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €1.10 Mil. Acrux's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €1.19 Mil. Acrux's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was €5.53 Mil. Acrux's debt to asset for the quarter that ended in Jun. 2024 was 0.41.

Acrux Debt-to-Asset Historical Data

The historical data trend for Acrux's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acrux Debt-to-Asset Chart

Acrux Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 0.10 0.15 0.18 0.41

Acrux Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.19 0.18 0.19 0.41

Competitive Comparison of Acrux's Debt-to-Asset

For the Biotechnology subindustry, Acrux's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acrux's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acrux's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Acrux's Debt-to-Asset falls into.


Acrux Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Acrux's Debt-to-Asset for the fiscal year that ended in Jun. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(1.098 + 1.187) / 5.529
=0.41

Acrux's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(1.098 + 1.187) / 5.529
=0.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acrux  (FRA:FJY) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Acrux Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Acrux's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Acrux Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acrux Ltd (FRA:FJY) » Definitions » Debt-to-Asset
Comparable Companies
ASX:1AD ASX:1AI ASX:ANR ASX:MEM ASX:TRP ASX:ATH ASX:PAB ASX:IMC ASX:CHM ASX:BIT VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
ARUXF:USA ACR:Australia
Address
103-113 Stanley Street, West Melbourne, Melbourne, VIC, AUS, 3003
Website
https://www.acrux.com.au
Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and other countries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline products include Lenzetto, Evamist, Testosterone Topical Solution, and among others.

Acrux Headlines

No Headlines